LUMIRABIO JOURNAL
Perspectives on peptide development, analysis and sourcing.
15 articles9–12 / 15
A familiar molecule name and a polished CoA are not enough if the manufacturing site, batch history, analytical controls, and U.S. import roles cannot be reconciled. FDA Import Alert 66-80 gives GLP-1 API buyers a practical framework for asking those questions before shipment.
Read article
Six trends are shaping peptide development: FDA reviews, multi-agonist trials, amylin combinations and AI-assisted design are among them. Each creates new choices for developers. Each also brings specific needs for chemistry, manufacturing and controls (CMC) evidence.
Read article
Modern metabolic drug programs increasingly build on peptide hormones such as GLP-1, GIP and amylin. The reason lies in receptor biology, while successful products also depend on half-life engineering, delivery technology and rigorous CMC control.
Read article
Endogenous peptides form a diverse communication network across endocrine, neural, metabolic and immune pathways. Understanding how those signals are produced, received and cleared gives peptide discovery and CMC teams a more useful starting point than treating peptides as a single therapeutic class.
Read article